Infliximab for the treatment of pediatric ulcerative colitis

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 6, 2012, Pages 659-665

  Bradley, Gia M ^a   Oliva Hemker, Maria ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti TNF agents; inflammatory bowel disease; infliximab; ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CHIMERIC ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; CHILD; CHILD CARE; CHILL; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; FACE EDEMA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAND EDEMA; HEPATITIS B; HEPATOSPLENIC T CELL LYMPHOMA; HOSPITALIZATION; HUMAN; HYPOTENSION; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; PEDIATRIC ULCERATIVE COLITIS ACTIVITY INDEX; PHARMACODYNAMICS; PROGNOSIS; REVIEW; SCORING SYSTEM; SERUM SICKNESS; SINGLE DRUG DOSE; T CELL LYMPHOMA; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; COLITIS, ULCERATIVE; HUMANS;

EID: 84870982978     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.53     Document Type: Review

References (66)

1. Hyams JS. Inflammatory bowel disease. Pediatr. Rev. 26(9), 314-320 (2005).
2. Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. 58(2), 139-157 (2006). (Pubitemid 43874878)
3. Waterman M, Xu W, Stempak JM et al. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm. Bowel Dis. 17(9), 1936-1942 (2011).
4. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J. Gastroenterol. Hepatol. 25(2), 325-333 (2010).
5. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch. Dis. Child. 88(11), 995-1000 (2003). (Pubitemid 37449406)
6. Uchida K, Araki T, Toiyama Y et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis. Colon Rectum 49(1), 74-79 (2006). (Pubitemid 41830658)
7. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin. Pediatr. Surg. 16(3), 164-171 (2007). (Pubitemid 46977778)
8. Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch-anal anastomosis on female fertility: meta- analysis and systematic review. Int. J. Colorectal Dis. 26(11), 1365-1374 (2011).
9. Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin. Pharmacother. 7(14), 1907-1918 (2006). (Pubitemid 44489365)
10. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol. Clin. North Am. 38(4), 577-594 (2009).
11. Dagata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm. Bowel Dis. 2(4), 229-235 (1996). (Pubitemid 126727733)
12. Hyams J, Markowitz J, Lerer T et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin. Gastroenterol. Hepatol. 4(9), 1118-1123 (2006). (Pubitemid 44311638)
13. Hyams JS, Lerer T, Mack D et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am. J. Gastroenterol. 106(5), 981-987 (2011).
14. Castro M, Papadatou B, Ceriati E et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch. Surg. 392(2), 161-164 (2007). (Pubitemid 46328683)
15. Hyams J, Damaraju L, Blank M et al.; T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 10(4), 391-399.e1 (2012).
16. Khan KJ, Ullman TA, Ford AC et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and metaanalysis. Am. J. Gastroenterol. 106(4), 661-673 (2011).
17. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 104(2), 437-443 (2009).
18. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2(9), 731-743 (2004). (Pubitemid 39200711)
19. Bradley GM, Oliva-Hemker M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 6, 125-134 (2012).
20. Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 67(12), 1703-1723 (2007). (Pubitemid 47263178)
21. Smolen JS, Aletaha D. Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1(2), 62-63 (2005).
22. Hanauer SB, Feagan BG, Lichtenstein GR et al.; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002). (Pubitemid 34621118)
23. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004). (Pubitemid 38252535)
24. Hyams J, Crandall W, Kugathasan S et al.; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132(3), 863-873; quiz 1165 (2007). (Pubitemid 46454266)
25. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005). (Pubitemid 41770166)
26. Mamula P, Markowitz JE, Brown KA, Hurd LB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 34(3), 307-311 (2002). (Pubitemid 34437526)
27. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. 38(3), 298-301 (2004).
28. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 39(2), 166-170 (2004).
29. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11(3), 213-218 (2005). (Pubitemid 40439675)
30. Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 44(3), 312-317 (2007). (Pubitemid 46673377)
31. Cucchiara S, Romeo E, Viola F et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig. Liver Dis. 40(Suppl. 2), S260-S264 (2008). (Pubitemid 351878069)
32. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J. Clin. Gastroenterol. 42(8), 875-879 (2008).
33. Hyams JS, Lerer T, Griffiths A et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Outcome following infliximab therapy in children with ulcerative colitis. Am. J. Gastroenterol. 105(6), 1430-1436 (2010).
34. Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J. Pediatr. Gastroenterol. Nutr. 50(6), 628-633 (2010).
35. Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106(6), 1455-1466 (1994). (Pubitemid 24163114)
36. Reinecker HC, Steffen M, Witthoeft T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94(1), 174-181 (1993). (Pubitemid 23308385)
37. Cornillie F, Shealy D, D'Haens G et al. Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment. Pharmacol. Ther. 15(4), 463-473 (2001). (Pubitemid 32242771)
38. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124(7), 1774-1785 (2003). (Pubitemid 36666774)
39. Baert FJ, D'Haens GR, Peeters M et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology 116(1), 22-28 (1999). (Pubitemid 29013489)
40. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119(4), 1148-1157 (2000).
41. Danese S, Sans M, Scaldaferri F et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel antiinflammatory mechanism of infliximab in Crohn's disease. J. Immunol. 176(4), 2617-2624 (2006). (Pubitemid 43201714)
42. Fasanmade AA, Adedokun OJ, Ford J et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 65(12), 1211-1228 (2009).
43. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 Phase III clinical trials. Clin. Ther. 33(7), 946-964 (2011).
44. Turner D, Mack D, Leleiko N et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 138(7), 2282-2291 (2010).
45. Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133(2), 423-432 (2007). (Pubitemid 47193130)
46. Turner D, Hyams J, Markowitz J et al.; Pediatric IBD Collaborative Research Group. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm. Bowel Dis. 15(8), 1218-1223 (2009).
47. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 20(2), 100-108 (2009).
48. Toussirot E, Houvenagel E, Goeb V et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine doi:10.1016/j.jbspin.2011.10.001 (2011) (Epub ahead of print).
49. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45(2), 55-57 (2009).
50. Jacobstein DA, Markowitz JE, Kirschner BS et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. 11(5), 442-446 (2005). (Pubitemid 40704078)
51. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J. Pediatr. Gastroenterol. Nutr. 38(5), 502-508 (2004).
52. Lamireau T, Cézard JP, Dabadie A et al.; French-Speaking Group for Pediatric Gastroenterology Nutrition. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm. Bowel Dis. 10(6), 745-750 (2004). (Pubitemid 39545219)
53. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38(9), 1261-1265 (2004). (Pubitemid 38608568)
54. Pérez-Alvarez R, Díaz-Lagares C, García- Hernández F et al.; BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90(6), 359-371 (2011).
55. Ferkolj I. How to improve the safety of biologic therapy in Crohn's disease. J. Physiol. Pharmacol. 60(Suppl. 7), 67-70 (2009).
56. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 62(8), 2517-2524 (2010).
57. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. 13(8), 1024-1030 (2007). (Pubitemid 47309975)
58. Sprakes MB, Ford AC, Suares NC et al. Costs of care for Crohn's disease following the introduction of infliximab: a singlecentre UK experience. Aliment. Pharmacol. Ther. 32(11-12), 1357-1363 (2010).
59. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderateto- severe ulcerative colitis. Gastroenterology 142(2), 257-265.e1 (2012).
60. Hyams JS, Griffiths A, Markowitz J et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 143(2), 365-374.e2 (2012).
61. Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev. Clin. Immunol. 6(4), 659-666 (2010).
62. Alexander F. Complications of ileal pouch anal anastomosis. Semin. Pediatr. Surg. 16(3), 200-204 (2007). (Pubitemid 46977783)
63. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Oøstergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand. J. Gastroenterol. 47(5), 518-527 (2012).
64. Kugathasan S, Levy MB, Saeian K et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol. 97(6), 1408-1414 (2002). (Pubitemid 34664785)
65. Domènech E, Zabana Y, Mañosa M, Garcia-Planella E, Cabré E, Gassull MA. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a threeinfusion induction regimen. J. Clin. Gastroenterol. 44(1), 34-37 (2010).
66. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 60(12), 1739-1753 (2011).